Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 26, No 4 (February 1), 2008: pp. 690
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.14.5490

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Froehner, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Froehner, M.
Related Articles
Right arrowRelated Reply
Right arrowRelated Article

CORRESPONDENCE

Life Expectancy Estimation by Nomogram

Michael Froehner

Department of Urology, University Hospital "Carl Gustav Carus," Technical University of Dresden, Dresden, Germany

To the Editor:

I read with great interest the article by Walz et al1 introducing a new nomogram predicting 10-year overall survival in men with early prostate cancer. This meritorious study was based on a huge sample with long-term follow-up. The way of patient selection, however, could be a source of bias that clinicians should keep in mind when applying the suggested nomogram. The authors included in the radiotherapy cohort-only patients without any hormonal manipulation. The overall survival curve in the resulting population compares unfavorably with other radiotherapy series2,4 and even with expectant management series3,4 and is similar to survival curves in men with severe comorbidity (Charlson score 2 or higher) treated by radiotherapy or expectant management in the pre-PSA–era.2 It is conceivable that the exclusion of hormonal therapy additionally to radiotherapy selected a sample with a particularly poor prognosis (without clinical failure due to early death of competing causes). Therefore, the results of the study should be interpreted with caution. The conclusion that the developed nomogram may "accurately identify those individuals who do not have sufficient life expectancy to warrant definitive prostate cancer treatment" is possibly too optimistic.

AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The author(s) indicated no potential conflicts of interest.

REFERENCES

1. Walz J, Gallina A, Saad F, et al: A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 25:3576-3581, 2007[Abstract/Free Full Text]

2. Barry MJ, Albertsen PC, Bagshaw MA, et al: Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: A retrospective analysis. Cancer 91:2302-2314, 2001[CrossRef][Medline]

3. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360:103-106, 2002[CrossRef][Medline]

4. Albertsen PC, Hanley JA, Penson DF, et al: 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol 177:932-936, 2007[CrossRef][Medline]


Related Reply

  • In Reply
    Nazareno Suardi, Claudio Jeldres, Pierre I. Karakiewicz, and Shahrokh Shariat
    JCO 2008 26: 691-693 [Full Text]

Related Article

  • A Nomogram Predicting 10-Year Life Expectancy in Candidates for Radical Prostatectomy or Radiotherapy for Prostate Cancer
    Jochen Walz, Andrea Gallina, Fred Saad, Francesco Montorsi, Paul Perrotte, Shahrokh F. Shariat, Claudio Jeldres, Markus Graefen, Francois Bénard, Michael McCormack, Luc Valiquette, and Pierre I. Karakiewicz
    JCO 2007 25: 3576-3581 [Abstract] [Full Text]



This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Froehner, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Froehner, M.
Related Articles
Right arrowRelated Reply
Right arrowRelated Article

About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online